SCHEMBL29975503

SCHEMBL29975503

CC(C)c1cc2ccc(Br)cc2nc1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.50
PABPC1 P11940 1/20 0.40
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 3/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
CYP2A6 P11509 1/20 0.35
TLR8 Q9NR97 2/20 0.35
LMNA P02545 2/20 0.34
ACHE P22303 2/20 0.34
F2 P00734 1/20 0.34
CHRM2 P08172 1/20 0.34
HTR1A P08908 1/20 0.34
ADRA2A P08913 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
MAOA P21397 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21129800 1.00 BACE1 (0.50) BACE1PABPC1MEN1KMT2AKDM4E
SCHEMBL30002881 0.83 BACE1 (0.50) BACE1PABPC1MEN1KMT2AKDM4E
SCHEMBL21682209 0.83 BACE1 (0.50) BACE1PABPC1MEN1KMT2AKDM4E
SCHEMBL22509693 0.81 NCK1 (0.46) BACE1MEN1KMT2AKDM4EALDH1A1
SCHEMBL22521518 0.81 NPC1 (0.44) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL8155187 0.79 BACE1 (0.42) BACE1PABPC1KMT2AKDM4EALDH1A1
SCHEMBL22521420 0.77 SCN10A (0.37) BACE1MEN1KMT2AALDH1A1MAPT
SCHEMBL8157695 0.77 BACE1 (0.40) BACE1HTTCYP1A2CYP2C19HTR1A
SCHEMBL22045308 0.77 TLR8 (0.57) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL21129799 0.77 BACE1 (0.55) BACE1PABPC1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11459330-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors LUPIN LIMITED (IN) 2022-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11459330-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors PRMT5, PRMT1, PRMT3 BACE1 1210/4885PABPC1 865/4885MEN1 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.